Arax Advisory Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$275K	Buy	839 +161	+24%	+$54.8K	0.01%	919
2025 Q4	$270K	Sell	678 -12,407	-95%	-$5.49M	0.01%	885
2025 Q3	$5.97M	Buy	13,085 +12,935	+8,623%	+$5.27M	0.09%	193
2025 Q2	$48.9K	Buy	150 +65	+76%	+$18K	﹤0.01%	1245
2025 Q1	$23K	Sell	85 -396	-82%	-$102K	﹤0.01%	1245
2024 Q4	$113K	Sell	481 -4	-0.8%	-$1.05K	0.01%	646
2024 Q3	$133K	Buy	485 +4	+0.8%	+$1.04K	0.01%	436
2024 Q2	$117K	Buy	+481	New	+$75.9K	0.01%	445
2024 Q1	–	Sell	-21	Closed	-$4.02K	–	1315
2023 Q4	$4.02K	Buy	21 +13	+163%	+$2.21K	﹤0.01%	923
2023 Q3	$1.42K	Buy	8 +5	+167%	+$954	﹤0.01%	1073
2023 Q2	$570	Sell	3 -5	-63%	-$991	﹤0.01%	1191
2023 Q1	$1.6K	Hold	8	–	–	﹤0.01%	1023
2022 Q4	$1.9K	Hold	8	–	–	﹤0.01%	954
2022 Q3	$2K	Buy	+8	New	+$1.53K	﹤0.01%	934